98D004A9-E3F0-448E-BFE2-359F25DF356C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 3.6465177398160313
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.722
- G2M_CHECKPOINT+0.693
- MYC_TARGETS_V2+0.641
- MYC_TARGETS_V1+0.602
- MITOTIC_SPINDLE+0.492
- DNA_REPAIR+0.448
- UNFOLDED_PROTEIN_RESPONSE+0.414
- WNT_BETA_CATENIN_SIGNALING+0.395
- TGF_BETA_SIGNALING+0.366
- MTORC1_SIGNALING+0.334
Top 10 suppressed
- KRAS_SIGNALING_DN-0.468
- PANCREAS_BETA_CELLS-0.387
- BILE_ACID_METABOLISM-0.358
- MYOGENESIS-0.325
- XENOBIOTIC_METABOLISM-0.244
- ESTROGEN_RESPONSE_LATE-0.231
- APICAL_SURFACE-0.228
- COAGULATION-0.191
- INFLAMMATORY_RESPONSE-0.177
- ESTROGEN_RESPONSE_EARLY-0.164
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.949 |
| 2 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.946 |
| 3 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.935 |
| 4 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.927 |
| 5 | 93123F83-44EC-4480-9453-F061AA7BC2DB | — | — | 0.911 |
| 6 | C4C1F171-9B72-4527-9C03-39C2C00A5B6C | — | — | 0.909 |
| 7 | SRR934902 | — | — | 0.909 |
| 8 | SRR934900 | — | — | 0.907 |
| 9 | SRR934748 | — | — | 0.904 |
| 10 | SRR934873 | — | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.722 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.693 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.641 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.602 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.492 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.448 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.414 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.395 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.366 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.334 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.281 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.227 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.226 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.213 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.159 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.149 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.142 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.134 | Idelalisib | — uncovered |